Avastin, Tamiflu depress Roche sales by 7%

Poor performance from its cancer star Avastin and falloff from last year's pandemic sales of Tamiflu pushed Roche's sales down by 7 percent to $12.1 billion, below analysts' estimates; the company expects global pricing pressures to cut revenue growth by two percentage points this year. Article | Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.